Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades, and initiations.
Top Wall Street analysts changed their outlook on these top names.
For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Deutsche Bank analyst David Hoang initiated coverage on Kymera Therapeutics Inc (NASDAQ:KYMR) with a Hold rating and announced a price target of $120.
Kymera Therapeutics shares closed at $105.25 on Wednesday.
See how other analysts view this stock.
Top Wall Street analysts changed outlook on top names. Analyst rating changes include upgrades, downgrades, and initiations. See…
Top Wall Street analysts change outlook on top names. See analyst ratings page for changes, including…
Top Wall Street analysts changed outlook on top names. See all analyst rating changes, including upgrades, downgrades and…
Wall Street analysts change outlook for top stocks. See upgrades, downgrades, and initiations on analyst ratings page. HSIC stock…
Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive…
Wall Street analysts change outlook on top stocks, including LIME, CIFR, BSP, DMRA, and ITG. Check analyst ratings page for full…
